Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 9/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067238 | 0.96 | NTSR1 (0.50) | NTSR1NTSR2SORT1OPRD1F2 | |
| SCHEMBL29569246 | 0.96 | NTSR1 (0.44) | NTSR1APLNRNTSR2SORT1OPRD1 | |
| SCHEMBL29800900 | 0.92 | NTSR1 (0.48) | NTSR1NTSR2SORT1OPRD1F2 | |
| SCHEMBL31067246 | 0.91 | PTPN1 (0.43) | NTSR1APLNRNTSR2OPRD1PTPN1 | |
| SCHEMBL29800934 | 0.90 | PTPN1 (0.42) | NTSR1APLNROPRD1PTPN1 | |
| SCHEMBL31748807 | 0.90 | NTSR1 (0.43) | NTSR1APLNRNTSR2SORT1OPRD1 | |
| SCHEMBL29801129 | 0.89 | PTPN1 (0.45) | NTSR1APLNROPRD1F2PTPN1 | |
| SCHEMBL30933084 | 0.89 | NTSR1 (0.49) | NTSR1APLNRNTSR2SORT1OPRD1 | |
| SCHEMBL31067241 | 0.88 | NTSR1 (0.55) | NTSR1NTSR2SORT1OPRD1F2 | |
| SCHEMBL29904041 | 0.87 | APLNR (0.41) | NTSR1APLNROPRD1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075389-A | Anti-inflammatory salidroside-promoting composite hydrogel and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075736-A | Tumor microenvironment responsive enzyme prodrug conversion nano-composite and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-115887688-B | Self-adaptive ischemic cerebral apoplexy drug delivery system and preparation method and application thereof | ZHEJIANG CHINESE MEDICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | claimed |
| US-20250215093-A1 | FUSION PROTEIN COMPRISING AN EGFR-BINDING DOMAIN AND A MASKING DOMAIN | ZYTOX THERAPEUTICS AB (SE) | 2025-07-03 | — | — | US | claimed |
| CN-119909165-A | Polypeptide hydrogel vaccine based on neoantigenic peptide and preparation method and application thereof | 上海交通大学 | 2025-05-02 | — | — | CN | claimed |
| CN-119874832-A | Preparation method and application of novel polypeptide fluorescent probe | 重庆医科大学 | 2025-04-25 | — | — | CN | claimed |
| EP-4529470-A1 | NEAR-INFRARED DYES AND CONJUGATES FOR TARGETING TUMORS | Lahjavida, LLC (US) | 2025-04-02 | — | — | EP | claimed |
| CN-119546342-A | Near infrared dyes and conjugates for targeting tumors | 拉加维达有限责任公司 | 2025-02-28 | — | — | CN | claimed |
| EP-4473014-A1 | FUSION PROTEIN COMPRISING AN EGFR-BINDING DOMAIN AND A MASKING DOMAIN | Zytox Therapeutics AB (SE) | 2024-12-11 | — | — | EP | claimed |
| CN-111154002-B | Bifunctional peptide K14, gene vector and co-drug delivery system | 上海海洋大学 | 2022-11-22 | — | — | CN | claimed |
| CN-114515277-B | Calcium ion nano chelating agent and preparation method and application thereof | 中国科学技术大学 | 2022-10-28 | — | — | CN | claimed |
| US-20220331441-A1 | Tumor-Targeting Polypeptide Nanoparticle Delivery System for Nucleic Acid Therapeutics | SIRNAOMICS, INC. | 2022-10-20 | — | — | US | claimed |
| EP-4069261-A2 | PEPTIDE DOCKING VEHICLE FOR TARGETED NUCLEIC ACID DELIVERY | Sirnaomics, Inc. (US) | 2022-10-12 | — | — | EP | claimed |
| CN-111110650-B | Preparation method of enzyme-sensitive amphiphilic polyester drug-loaded nanoparticles | 浙江工业大学 | 2022-09-20 | — | — | CN | claimed |
| CN-109589412-B | Drug-loaded succinylated gelatin-containing drug delivery system | 复旦大学 | 2022-08-26 | — | — | CN | claimed |
| EP-4037716-A1 | TUMOR-TARGETING POLYPEPTIDE NANOPARTICLE DELIVERY SYSTEM FOR NUCLEIC ACID THERAPEUTICS | Sirnaomics, Inc. (US) | 2022-08-10 | — | — | EP | claimed |
| CN-114885604-A | Peptide docking vectors for targeted delivery of nucleic acids | 圣诺制药公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114515277-A | Calcium ion nano chelating agent and preparation method and application thereof | 中国科学技术大学 | 2022-05-20 | — | — | CN | claimed |
| US-20220054645-A1 | Targeted Delivery of Therapeutic Molecules | Zhang, Peter (CN) | 2022-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054645-A1 | Targeted Delivery of Therapeutic Molecules | CD44, CD47, EPCAM | NTSR1 696/4885APLNR 51/4885NTSR2 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.